The government has joined hands with Prostate Cancer UK to launch a massive screening trial in the country next year.
Called TRANSFORM, the trial will use innovative screening methods like an MRI scan to detect prostate cancer, which is the most common cancer in men in the UK.
The trail is scheduled for launch in Spring 2024, and recruitment is likely to begin in Autumn 2024.
For the £42 million trial, the government will invest £16 million through the National Institute of Health Research, and £26m will be provided by Prostate Cancer UK.
The Department of Health and Social Care (DHSC) believes that thousands of men's lives could be saved each year if prostate cancer is detected early with
effective screening methods.
Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit,
boosting the Danish company's hopes of moving beyond its image as a lifestyle drug.
The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and
celebrities worldwide.
Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165
per cent over the past two years.
The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is
$1,300 a month in the United States, for a wider range of patients.
U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new
data could lead the U.S. government to reassess that.
The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and
diagnostics.
Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy.
This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated.
The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier
and better diagnostic technologies, to medical devices.
The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.